Posted by Michael Wonder on 08 Dec 2023
European Commission approves Pfizer’s Elrexfio for relapsed and refractory multiple myeloma
8 December 2023 - Conditional marketing authorisation is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial.
Pfizer today announced the European Commission (EC) has granted conditional marketing authorisation for Elrexfio (elranatamab).
